Finance

Lists
Q1 2027 earnings • released • EPS beat +64,70% • Revenue beat +0,52%
See results
ANGO:NASDAQ
AngioDynamics, Inc.
USD 11,23
-20,86%
(-2,96) 1D
USD 11,35
+1,07% (+0,12)
Pre-market
Closed: 8 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANGO...
Open
USD 13,22
High
USD 13,80
Low
USD 11,06
Mkt. cap
472,27 m
Avg. vol.
525,89 k
Volume
1,44 k
52-wk high
USD 16,29
52-wk low
USD 9,39
EPS
-USD 0,88
Beta
0,30
Shares outstanding
42,05 m
No. of employees
632
Open
USD 13,22
High
USD 13,80
Low
USD 11,06
Mkt. cap
472,27 m
Avg. vol.
525,89 k
Volume
1,44 k
52-wk high
USD 16,29
52-wk low
USD 9,39
EPS
-USD 0,88
Beta
0,30
Shares outstanding
42,05 m
No. of employees
632
News stories
From web sources and news partners
About AngioDynamics, Inc.
CEOJames Clemmer
Employees632
Founded09 Feb. 1988
Headquarters-
SectorMedical device
Websiteangiodynamics.com
Analyst ratings
Based on 3 analysts giving stock ratings to ANGO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ANGO in the last 3 months.
Highest
Current USD 11,23
USD 24,00 (+113,71%)
Average
USD 21,00 (+87,00%)
Lowest
USD 19,00 (+69,19%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Young CFA
Canaccord Genuity
Buy
Maintained
USD 20,00
+78,1%
08/11/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
USD 19,00
+69,2%
07/16/2026
Frank Takkinen
Lake Street
Buy
Maintained
USD 24,00
+113,7%
07/14/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Initiated
USD 16,00
+42,5%
04/06/2026
Last report
08 Okt. 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
-USD 0,04 / -USD 0,11
+64,70%beat
Revenue / Est. (USD)
80,92 m / 80,50 m
+0,52%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Aug. 2025
Nov. 2025
Feb. 2026
Mei 2026
Revenue
75,71 m
79,43 m
78,42 m
86,61 m
Cost of goods sold
33,85 m
34,65 m
36,94 m
39,83 m
Cost of revenue
33,85 m
34,65 m
36,94 m
39,83 m
Research and development expenses
6,32 m
7,63 m
6,93 m
8,03 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40,78 m
37,00 m
38,31 m
41,53 m
Operating expense
49,76 m
47,27 m
47,91 m
52,42 m
Total operating expenses
83,61 m
81,92 m
84,85 m
92,26 m
Operating income
-7,90 m
-2,49 m
-6,43 m
-5,65 m
Other non operating income
-178,00 k
-128,00 k
4,97 m
-735,00 k
EBT including unusual items
-10,84 m
-6,36 m
-8,07 m
-11,04 m
EBT excluding unusual items
-8,08 m
-2,72 m
-1,55 m
-6,49 m
Income tax expense
65,00 k
-5,00 k
12,00 k
370,00 k
Effective tax rate
-0,60%
0,08%
-0,15%
-3,35%
Other operating expenses
-
-
-
138,00 k
Net income
-10,90 m
-6,35 m
-8,08 m
-11,40 m
Net profit margin
-14,40%
-7,99%
-10,31%
-13,17%
Earnings per share
-0,10
-
0,02
-0,07
Interest and investment income
-
-
12,00 k
1,00 k
Interest expense
-4,00 k
-102,00 k
-100,00 k
-106,00 k
Net interest expenses
-4,00 k
-102,00 k
-88,00 k
-105,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,88 m
3,26 m
-838,00 k
-353,00 k
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme